van Broekhoven, Amber
Mohammadnia, Niekbachsh
Silvis, Max J. M.
Los, Jonathan
Fiolet, Aernoud T. L.
Opstal, Tjerk S. J.
Mosterd, Arend
Eikelboom, John W.
Nidorf, Stefan M.
Budgeon, Charley A.
Byrnes, Elizabeth
Bax, Willem A.
Tijssen, Jan G. P.
de Kleijn, Dominique P. V.
Thompson, Peter L.
El Messaoudi, Saloua
Cornel, Jan H. http://orcid.org/0000-0002-1006-2112
Clinical trials referenced in this document:
Documents that mention this clinical trial
The Effect of Years-Long Exposure to Low-Dose Colchicine on Renal and Liver Function and Blood Creatine Kinase Levels: Safety Insights from the Low-Dose ColchicineĀ 2 (LoDoCo2) Trial
https://doi.org/10.1007/s40261-022-01209-8
Funding for this research was provided by:
Withering Foundation the Netherlands
a consortium of Teva, Disphar, and Tiofarma in the Netherlands
the National Health Medical Research Council of Australia
Sir Charles Gairdner Research Advisory Committee
Hartstichting
Netherlands Organization for Health Research and Development
Article History
Accepted: 26 September 2022
First Online: 8 October 2022
Declarations
:
: This work was supported by the National Health Medical Research Council of Australia; a Grant from the Sir Charles Gairdner Research Advisory Committee; the Withering Foundation, The Netherlands; the Netherlands Heart Foundation; the Netherlands Organization for Health Research and Development; and a consortium of Teva, Disphar, and Tiofarma in The Netherlands.
: Amber van Broekhoven, Niekbachsh Mohammadnia, Max J.M. Silvis, Jonathan Los, Aernoud T. L. Fiolet, Tjerk S. J. Opstal, Stefan M. Nidorf, Charley A. Budgeon, Elizabeth Byrnes, Jan G. P. Tijssen, Dominique P. V. de Kleijn, and Saloua El Messaoudi have nothing to disclose. Arend Mosterd reports membership of advisory boards and/or consultancy for AstraZeneca, Bayer, Boehringer Ingelheim, and Novartis. He will not accept personal fees; these fees will be donated to research in The Netherlands. John W. Eikelboom reports consulting/honoraria support from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Eli Lilly, GlaxoSmithKline, Pfizer, Janssen, Sanofi-Aventis, and Servier, and grants and/or in-kind support from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Pfizer, Janssen, and Sanofi-Aventis. Willem A. Bax reports membership of advisory boards and/or honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, NovoNordisk, and Sanofi-Aventis. Jan H. Cornel reports membership of advisory boards with Amgen and AstraZeneca. Peter L. Thompson reports grants, travel support, and honoraria from Amarin, Amgen, AstraZeneca, Bristol Myers Squibb, Merck, and Pfizer.
: The trial protocol was approved by a centralized Institutional Review Board in each participating country.
: All participants gave their informed consent to have blood drawn at the close-out visit at the end of the LoDoCo2 trial.
: Not applicable.
: The data underlying this article will be shared upon reasonable request to the Steering Committee via the following e-mail address: A.Mosterd@meandermc.nl.
: Not applicable.
: All authors contributed to the conception of the strategy. The first draft of the manuscript was written by AB and NM, and all authors edited and commented on previous versions. All authors have read and approved the final manuscript.